SYRE · Spyre Therapeutics, Inc. · Documents
$95.51
-1.05 (-1.09%)
At close · Nov 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$8.37B
Shares
88.17M
Volume · Nov 2
752.11K
Avg daily vol (3M)
1.2M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Spyre Therapeutics, Inc. entered an underwriting agreement on October 5, 2026, offering 4,117,648 common shares at $85.00 per share, with a 30-day option for up to 617,647 additional shares; gross proceeds are expected to be approximately $350.0 million before expenses. | 2026-10-07 | 2026-10-05 | |
| Investor Event Transcript | — | 2026-09-10 | 2026-09-30 | |
| 8-K | — | 2026-09-08 | — | |
| 8-K | — | 2026-08-25 | — | |
| 8-K | — | 2026-08-04 | — | |
| 10-Q | — | 2026-08-04 | 2026-06-30 | |
| S-3ASR | — | 2026-06-26 | — | |
| 8-K | — | 2026-06-15 | — | |
| Investor Event Transcript | — | 2026-06-08 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-06-03 | 2026-06-30 | |
| 8-K | — | 2026-06-01 | 2026-05-29 | |
| 8-K | — | 2026-05-29 | 2026-05-27 | |
| 8-K | — | 2026-05-05 | — | |
| 10-Q | — | 2026-05-05 | 2026-03-31 | |
| 8-K | — | 2026-04-16 | 2026-04-14 | |
| 8-K | — | 2026-04-13 | — | |
| 8-K | — | 2026-04-13 | — | |
| DEFA14A | — | 2026-04-10 | — | |
| DEF 14A | — | 2026-04-10 | 2026-05-27 | |
| ARS | — | 2026-04-10 | 2025-12-31 | |
| 8-K | — | 2026-02-19 | — | |
| 10-K | — | 2026-02-19 | 2025-12-31 | |
| S-3 | — | 2026-02-19 | — | |
| 8-K | — | 2026-01-12 | — | |
| 10-Q | — | 2025-11-04 | 2025-09-30 | |
| 8-K | — | 2025-11-04 | — | |
| 8-K | — | 2025-10-15 | 2025-10-13 | |
| 8-K | — | 2025-10-14 | — | |
| 8-K | — | 2025-08-05 | — | |
| 10-Q | — | 2025-08-05 | 2025-06-30 | |
| 8-K | — | 2025-06-17 | — | |
| 8-K | — | 2025-06-02 | 2025-05-29 | |
| 8-K | — | 2025-05-08 | — | |
| 10-Q | — | 2025-05-08 | 2025-03-31 | |
| DEFA14A | — | 2025-04-14 | — | |
| ARS | — | 2025-04-14 | 2024-12-31 | |
| DEF 14A | — | 2025-04-14 | 2025-05-29 | |
| 8-K | — | 2025-03-06 | 2025-02-28 | |
| 8-K | — | 2025-02-27 | — | |
| 10-K | — | 2025-02-27 | 2024-12-31 | |
| S-3 | — | 2025-02-27 | — | |
| 8-K | — | 2025-01-13 | — | |
| 8-K | — | 2024-11-19 | 2024-11-18 | |
| 8-K | — | 2024-11-18 | — | |
| 10-Q/A | — | 2024-11-18 | 2024-03-31 | |
| 10-Q/A | — | 2024-11-18 | 2024-09-30 | |
| 10-Q/A | — | 2024-11-18 | 2024-06-30 | |
| 10-K/A | — | 2024-11-18 | 2023-12-31 | |
| 8-K | — | 2024-11-12 | — | |
| 8-K | — | 2024-11-07 | — |
Showing 1–50 of 188 filings
Key facts
CIK
1636282
CUSIP
00773J202
13F (30d)
44 filings
44 filers
Visit website
Investor relations